The EMA's human medicines committee has said it cannot approve Biogen and Eisai's Alzheimer's disease therapy Aduhelm, saying it was unconvinced by the data submitted for the drug.
Scientists in the US have found that people who use Viagra for erectile dysfunction seem to have a lower risk of developing Alzheimer's disease – a link that they say should be examined mor
Novartis has licensed a potential drug for Parkinson's from Belgium's UCB that it thinks could be the first oral, disease-modifying drug for the disease – if it can avoid the fate of earlie
Biogen and Eisai have said that the EMA's human medicines committee looks unlikely recommended approval of their Alzheimer's drug Aduhelm when it comes up for discussion next month.
AbbVie has reported that a subcutaneous infusion of Parkinson's disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving the way for regulatory fi
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.